Quince completes Phase 3 NEAT enrollment; Q2 net loss $16.1M

Quince Therapeutics, Inc.

2025-Q2 EPS reported -$0.69

Pivotal Phase 3 NEAT trial enrollment completed with 105 participants; topline results expected Q1 2026.
Cash $34.7M; private placement raised ~$11.5M upfront at >10% premium, potential $10.4M from warrants.
Q2 net loss $16.1M ($0.34/shr); R&D $6.6M, G&A $3.3M; cash runway into Q2 2026.
Strategic relationship with Option Care Health (OPCH) to support U.S. commercial launch of eDSP.
New SAB member Dr. Hassan Abolhassani appointed; Phase 2 DMD study design finalized.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.